Microbix Biosystems presenting results of QAP at ESCMID Global 2026

Microbix Biosystems (MBXBF) will be exhibiting at ESCMID Global 2026 and presenting results of a novel quality assessment product to enable full-process quality management of molecular assays to detect an RNA-based virus. At ESCMID Global, Microbix will be showcasing its QAPs innovations for helping to ensure the accuracy of diagnostic tests, including for bacterial, fungal, parasitic, and viral diseases, and in multiple formats, such as liquid-vials and on Copan FLOQSwabs. Additionally, Microbix will be presenting information about its QUANTDx quantified reference materials that are used to support the development of new assays relating to multiplex/syndromic, viral variant, antimicrobial resistance, genetics, oncology, or molecular pathology tests. The Microbix team looks forward to meeting with current and prospective clients and determining how best to support their assay development or QMS needs. Also at ESCMID Global, Microbix is presenting its poster titled “Development of non-infectious phage-encapsulated RNA control to support PCR assay development during outbreaks of viral pathogens.” Authored by Microbix Scientist Leyla El Ayoubi and colleagues, the poster will be presented during the Outbreaks and Public Health Emergencies session of the Congress and describes the successful creation and validation of a mimetic of the Hepatitis C virus, a pathogen with a genome formed of Ribonucleic Acids. Unlike the patient-samples often used for quality management of HCV tests, the novel Microbix QAP is safe, stable, and fully-reproducible – being comprised of an inactive RNA genome encapsulated within a bacteriophage and thereby providing a broadly compatible whole-process control.